BLATNÝ, Jan, Dagmar SEIDLOVÁ, Miroslav PENKA, Petra OVESNÁ, Petr BRABEC, Pavel ŠEVČÍK, Pavel VENTRUBA and V. ČERNÝ. Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry. International journal of obstetric anesthesia. 2011, vol. 20, No 4, p. 367-368. ISSN 0959-289X. Available from: https://dx.doi.org/10.1016/j.ijoa.2011.07.008.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry
Authors BLATNÝ, Jan (203 Czech Republic, guarantor, belonging to the institution), Dagmar SEIDLOVÁ (203 Czech Republic, belonging to the institution), Miroslav PENKA (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Petr BRABEC (203 Czech Republic, belonging to the institution), Pavel ŠEVČÍK (203 Czech Republic, belonging to the institution), Pavel VENTRUBA (203 Czech Republic, belonging to the institution) and V. ČERNÝ (203 Czech Republic).
Edition International journal of obstetric anesthesia, 2011, 0959-289X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30214 Obstetrics and gynaecology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.395
RIV identification code RIV/00216224:14110/11:00054077
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ijoa.2011.07.008
UT WoS 000297087100026
Keywords in English UniSeven registry; postpartum haemorrhage
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 23/3/2012 13:52.
Abstract
All cases between 2004 and 2009 in which rFVIIa was used to treat PPH in Czech patients without a primary coagulation defect were identified. Demographic and clinical data were extracted from the selected records (these were incomplete in three cases) and compared in women who received rFVIIa before proposed hysterectomy and those who were given rFVIIa during or after hysterectomy. Treatment with rFVIIa was considered to be effective if the patient survived; saving the uterus was considered to be a secondary benefit of treatment.
PrintDisplayed: 31/5/2024 23:25